乳腺癌患者详细超声心动图表型分析:与射血分数下降、恢复及心力衰竭症状在3年随访中的关联
该前瞻性纵向队列研究纳入277例接受多柔比星、曲妥珠单抗或两者联合的乳腺癌患者,中位随访2.0年获取1249次超声心动图。多柔比星和曲妥珠单抗导致3年内左心室射血分数轻度持续下降;容量、应变和心室-动脉耦合指标的变化与射血分数下降及恢复一致相关。
要点
- 多柔比星联合曲妥珠单抗组1年LVEF下降最大(-6.6%),3年部分恢复(-2.8%)。
- LVEF下降和恢复主要与收缩容积、纵向和环向应变及Ea/Eessb变化相关。
- 4-6个月早期容量、应变和Ea/Eessb变化与1年和2年LVEF变化相关。
核心结论
- 多柔比星和曲妥珠单抗导致3年内左心室射血分数轻度持续下降。
- 容量、应变和心室-动脉耦合的变化在不同治疗间一致地与同期及后续LVEF下降和恢复相关。
研究设计与样本
- 前瞻性纵向队列研究,纳入277例接受多柔比星、曲妥珠单抗或两者联合的乳腺癌参与者。
- 中位随访2.0年(四分位距1.0-3.0年),共获取1249次超声心动图。
- 超声心动图参数在核心实验室以盲法量化。
主要发现
- 多柔比星组1年LVEF变化-3.6%(95%CI -4.4%至-2.8%),3年变化-3.8%(95%CI -5.1%至-2.5%)。
- 曲妥珠单抗组1年LVEF变化-4.5%(95%CI -6.0%至-2.9%),3年变化-2.8%(95%CI -5.3至-0.4)。
- 多柔比星联合曲妥珠单抗组1年LVEF下降最大(-6.6%,95%CI -8.2至-5.0),3年部分恢复(-2.8%,95%CI -4.8至-0.8)。
- LVEF下降和恢复主要与收缩容积、纵向和环向应变及Ea/Eessb变化相关,无证据表明治疗间存在效应修饰。
- 4-6个月时容量、应变和Ea/Eessb的早期变化与1年和2年LVEF变化相关;应变和Ea的早期变化与1年心力衰竭症状加重相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease in patients with breast cancer is of growing concern. The longitudinal effects of commonly used therapies, including doxorubicin and trastuzumab, on cardiac remodeling and function remain unknown in this population. We aimed to define the changes in echocardiographic parameters of structure, function, and ventricular-arterial coupling, and their associations with left ventricular ejection fraction (LVEF) and heart failure symptoms. METHODS: In a longitudinal prospective cohort study of 277 breast cancer participants receiving doxorubicin (Dox), trastuzumab (Tras), or both (Dox+Tras), we obtained 1249 echocardiograms over a median follow-up of 2.0 (interquartile range, 1.0-3.0) years. Left ventricular structure, diastolic and contractile function, and ventricular-arterial coupling measures were quantified in a core laboratory blinded to participant characteristics. We evaluated changes in echocardiographic parameters over time, and used repeated-measures regression models to define their association with LVEF decline and recovery. Linear regression models defined the association between early changes in these parameters and subsequent changes in LVEF and heart failure symptoms. RESULTS: Overall, 177 (64%) received Dox, 51 (18%) received Tras, and 49 (18%) received Dox+Tras. With Dox, there was a sustained, modest decrease in LVEF over the follow-up duration (1-year change in LVEF -3.6%; 95% confidence interval [CI], -4.4% to -2.8%; 3-year change -3.8%; 95% CI, -5.1% to -2.5%). With Tras, a similar LVEF decline was observed at 1 year (-4.5%; 95% CI, -6.0% to -2.9%) and 3 years (-2.8%; 95%CI, -5.3 to -0.4%). Participants receiving Dox+Tras demonstrated the greatest declines at 1 year (-6.6%; 95% CI, -8.2 to -5.0%), with partial recovery at 3 years (-2.8%; 95% CI, -4.8 to -0.8%). LVEF declines and recovery were associated primarily with changes in systolic volumes, longitudinal and circumferential strain, and ventricular-arterial coupling indices, effective arterial elastance (Ea) and the coupling ratio Ea/Eessb, without evidence for effect modification across therapies. Early changes in volumes, strain, and Ea/Eessb at 4 to 6 months were associated with 1- and 2-year LVEF changes. Similarly, early changes in strain and Ea were associated with worsening heart failure symptoms at 1 year. CONCLUSIONS: Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
引用
- Narayan HK, Finkelman B, French B, et al. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation. 2017. PMID: 28104715. doi:10.1161/CIRCULATIONAHA.116.023463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。